# Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

> **NCT04572893** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 41 (actual)

## Conditions studied

- Primary Familial Dilated Cardiomyopathy

## Interventions

- **DRUG:** danicamtiv

## Key facts

- **NCT ID:** NCT04572893
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-04
- **Primary completion:** 2024-02-22
- **Final completion:** 2024-02-22
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572893, "Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04572893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*